Trade Vitrolife - VITR CFD

Add to favourite

165.6

8.81%

3.2

Low: 157.2

High: 177.2

Market Trading Hours* (UTC) Open now
Closes on Friday at 15:25

Mon - Fri: 07:00 - 15:25

Summary
Historical Data
Events
Income Statement
Balance Sheet

Trading сonditions

Spread

3.2

Long position overnight fee

-0.021944%

Short position overnight fee

-0.000278%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

SEK

Margin

Stock exchange

Sweden

Commission on trade

*Information provided by Capital.com

Key Stats

Prev. Close*	181.6
Open*	175.4
1-Year Change*	-17.65%
Day's Range*	157.2 - 177.2
52 wk Range	123.90-269.60
Average Volume (10 days)	230.68K
Average Volume (3 months)	3.94M
Market Cap	23.04B
P/E Ratio	57.29
Shares Outstanding	135.45M
Revenue	3.46B
EPS	2.97
Dividend (Yield %)	0.49971
Beta	1.86
Next Earnings Date	Feb 2, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 18, 2024	165.6	-13.4	-7.49%	179.0	179.6	157.2
Apr 17, 2024	181.6	1.4	0.78%	180.2	185.2	178.2
Apr 16, 2024	185.0	0.6	0.33%	184.4	189.0	179.4
Apr 15, 2024	189.8	3.0	1.61%	186.8	192.6	184.2
Apr 12, 2024	189.4	0.6	0.32%	188.8	193.0	185.0
Apr 11, 2024	187.8	6.8	3.76%	181.0	189.8	178.0
Apr 10, 2024	183.8	1.2	0.66%	182.6	187.8	180.0
Apr 9, 2024	185.0	2.0	1.09%	183.0	187.2	180.0
Apr 8, 2024	185.2	2.2	1.20%	183.0	186.0	178.4
Apr 5, 2024	183.0	-2.8	-1.51%	185.8	186.2	177.6
Apr 4, 2024	190.0	1.8	0.96%	188.2	191.8	187.4
Apr 3, 2024	189.4	1.0	0.53%	188.4	190.4	184.6
Apr 2, 2024	188.4	-9.8	-4.94%	198.2	200.4	185.4
Mar 28, 2024	200.2	3.4	1.73%	196.8	200.4	195.8
Mar 27, 2024	198.0	5.4	2.80%	192.6	199.8	192.6
Mar 26, 2024	197.2	1.8	0.92%	195.4	197.8	192.0
Mar 25, 2024	195.4	3.6	1.88%	191.8	197.6	191.2
Mar 22, 2024	193.6	0.2	0.10%	193.4	199.0	190.6
Mar 21, 2024	198.8	0.0	0.00%	198.8	200.8	190.0
Mar 20, 2024	196.6	4.6	2.40%	192.0	198.8	190.0

Vitrolife Events

Time (UTC)	Country	Event
Thursday, April 25, 2024
Time (UTC) 02:00	Country SE	Event Vitrolife AB Annual Shareholders Meeting Vitrolife AB Annual Shareholders Meeting Forecast - Previous -
Friday, April 26, 2024
Time (UTC) 12:00	Country SE	Event Vitrolife AB Vitrolife AB Forecast - Previous -
Time (UTC) 12:00	Country SE	Event Vitrolife AB Vitrolife AB Forecast - Previous -
Friday, July 12, 2024
Time (UTC) 06:30	Country SE	Event Q2 2024 Vitrolife AB Earnings Release Q2 2024 Vitrolife AB Earnings Release Forecast - Previous -
Time (UTC) 08:00	Country SE	Event Q2 2024 Vitrolife AB Earnings Call Q2 2024 Vitrolife AB Earnings Call Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	3234	1680.8	1245.57	1480.13	1151.35
Revenue	3234	1680.8	1245.57	1480.13	1151.35
Cost of Revenue, Total	1454	634.714	477.905	541.48	390.224
Gross Profit	1780	1046.09	767.667	938.652	761.124
Total Operating Expense	2602	1245.43	875.557	992.186	757.433
Selling/General/Admin. Expenses, Total	787	467.794	293.688	335.715	279.775
Research & Development	132	112.447	88.092	93.575	70.542
Depreciation / Amortization	226	37.95	21.33	21.189	5.15
Interest Expense (Income) - Net Operating	-3	-8.309	5.744	0.037	3.963
Unusual Expense (Income)	23	-1.342	-8.65	0.276	16.285
Other Operating Expenses, Total	-17	2.171	-2.552	-0.086	-8.506
Operating Income	632	435.379	370.015	487.946	393.915
Interest Income (Expense), Net Non-Operating	-79	24.937	-3.832	4.702	4.692
Other, Net	-16	-0.347	0.008	0.046	-0.024
Net Income Before Taxes	537	459.969	366.191	492.694	398.583
Net Income After Taxes	394	343.564	287.866	383.839	310.697
Minority Interest	0	-2.591	-1.02	-1.054	-1
Net Income Before Extra. Items	394	340.973	286.846	382.785	309.697
Net Income	394	340.973	286.846	382.785	309.697
Income Available to Common Excl. Extra. Items	394	340.973	286.845	382.785	309.697
Income Available to Common Incl. Extra. Items	394	340.973	286.845	382.785	309.697
Diluted Net Income	394	340.973	286.845	382.785	309.697
Diluted Weighted Average Shares	135.395	114.625	108.551	108.551	108.551
Diluted EPS Excluding Extraordinary Items	2.91001	2.97468	2.6425	3.52633	2.85302
Dividends per Share - Common Stock Primary Issue	0.85	0.8	0.8	0	0.85
Diluted Normalized EPS	3.03465	3.62408	2.57986	3.52831	2.96996
Total Adjustments to Net Income		0	-0.001

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	905	854	855	798	829
Revenue	905	854	855	798	829
Cost of Revenue, Total	400	369	392	371	359
Gross Profit	505	485	463	427	470
Total Operating Expense	717	695	687	621	654
Selling/General/Admin. Expenses, Total	282	286	266	241	254
Research & Development	33	34	23	33	43
Other Operating Expenses, Total	2	6	6	-24	-2
Operating Income	188	159	168	177	175
Interest Income (Expense), Net Non-Operating	-53	-29		-29	-6
Net Income Before Taxes	135	130	106	149	169
Net Income After Taxes	106	99	73	108	130
Minority Interest	0	1	1	0	0
Net Income Before Extra. Items	106	100	74	108	130
Net Income	106	100	74	108	130
Total Adjustments to Net Income		0			0
Income Available to Common Excl. Extra. Items	106	100	74	108	130
Income Available to Common Incl. Extra. Items	106	100	74	108	130
Diluted Net Income	106	100	74	108	130
Diluted Weighted Average Shares	135.395	135.395	135.395	135.395	135.395
Diluted EPS Excluding Extraordinary Items	0.7829	0.73858	0.54655	0.79767	0.96016
Dividends per Share - Common Stock Primary Issue	0	0	0.85	0	0
Diluted Normalized EPS	0.7829	0.73858	0.54655	0.79767	0.96016
Other, Net			-62	1

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	1572	1406.6	1414.44	1150.22	850.576
Cash and Short Term Investments	578	630.094	973.566	689.538	490.81
Cash				689.538	490.81
Total Receivables, Net	542	431.156	225.786	240.179	189.231
Accounts Receivable - Trade, Net	454	391.4	216.494	233.321	181.002
Total Inventory	405	312.894	204.027	208.82	161.186
Prepaid Expenses	47	32.457	11.063	11.687	9.349
Total Assets	20551	19428.8	2305.09	2138.69	1697.47
Property/Plant/Equipment, Total - Net	318	332.974	142.113	173.359	94.126
Property/Plant/Equipment, Total - Gross	763	670.152	331.608	346.227	238.758
Accumulated Depreciation, Total	-445	-337.178	-189.496	-172.87	-144.631
Goodwill, Net	13874	12994.6	403.239	425.842	421.611
Intangibles, Net	4648	4552.9	299.481	352.415	306.386
Long Term Investments	36	49.224	39.46	32.674	23.602
Other Long Term Assets, Total	103	92.473	6.354	4.173	1.166
Total Current Liabilities	621	954.326	177.014	202.352	152.275
Accounts Payable	181	173.081	25.922	29.314	32.085
Accrued Expenses	134	206.528	77.454	86.23	64.526
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases	182	455.673	13.593	14.632	0
Other Current Liabilities, Total	124	119.044	60.045	72.176	55.664
Total Liabilities	3815	4106.62	292.519	344.664	204.553
Total Long Term Debt	2043	2026.82	48.81	61.213	0
Long Term Debt	1988	1944.47			0
Deferred Income Tax	1102	1068.7	16.211	27.273	29.329
Minority Interest	4	18.695	4.444	3.605	3.298
Other Liabilities, Total	45	38.083	46.04	50.221	19.651
Total Equity	16736	15322.2	2012.57	1794.02	1492.91
Common Stock	28	27.631	22.144	22.144	22.144
Additional Paid-In Capital	13544	13544	494.61	494.61	494.61
Retained Earnings (Accumulated Deficit)	3164	1750.57	1495.82	1277.27	976.16
Total Liabilities & Shareholders’ Equity	20551	19428.8	2305.09	2138.69	1697.47
Total Common Shares Outstanding	135.395	135.395	108.551	108.551	108.551
Capital Lease Obligations	55	82.355	48.81	61.213
Cash & Equivalents	578	630.094	973.566

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	1825	1816	1653	1572	1408
Cash and Short Term Investments	778	687	618	578	461
Cash & Equivalents	778	687	618	578	461
Total Receivables, Net	535	612	573	542	492
Accounts Receivable - Trade, Net	480	542	495	454	433
Total Inventory	452	450	418	405	401
Prepaid Expenses	60	68	45	47	53
Other Current Assets, Total		-1	-1		1
Total Assets	21180	21648	20762	20551	20206
Property/Plant/Equipment, Total - Net	353	349	307	318	342
Goodwill, Net	14244	14552	14025	13874	13696
Intangibles, Net	4573	4755	4629	4648	4635
Long Term Investments	49	47	38	36	36
Other Long Term Assets, Total	136	129	110	103	89
Total Current Liabilities	596	651	596	621	670
Accounts Payable	163	224	174	181	201
Accrued Expenses	163	183	185	180	168
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases	145	149	148	182	199
Other Current Liabilities, Total	125	95	89	78	102
Total Liabilities	3750	3971	3749	3815	3820
Total Long Term Debt	2011	2125	2007	2043	2009
Long Term Debt	1941	2050	1959	1988	1949
Capital Lease Obligations	70	75	48	55	60
Deferred Income Tax	1085	1132	1097	1102	1081
Minority Interest	1	2	2	4	16
Other Liabilities, Total	57	61	47	45	44
Total Equity	17430	17677	17013	16736	16386
Common Stock	28	28	28	28	28
Additional Paid-In Capital	13544	13544	13544	13544	13544
Retained Earnings (Accumulated Deficit)	3858	4105	3441	3164	2815
Other Equity, Total					-1
Total Liabilities & Shareholders’ Equity	21180	21648	20762	20551	20206
Total Common Shares Outstanding	135.447	135.447	135.447	135.395	135.395

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Vitrolife Company profile

About Vitrolife AB

Vitrolife AB is a Sweden-based company engaged in assisted reproduction services. The Company’s product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. It also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The Company is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Vitrolife AB revenues increased 35% to SEK1.68B. Net income applicable to common stockholders increased 19% to SEK341M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Dividend per share remained flat at SEK0.80. Basic Earnings per Share excluding Extraordinary Items increased from SEK2.64 to SEK2.97.

Equity composition

1999: Stock Split in the ratio 1:2. 5/2018, 5-for-1 stock split (Factor: 5).

Industry:

Laboratory Diagnostic & Testing Substances

Gustaf Werners gata 2
Västra Frölunda
GOETEBORG
VASTRA GOTALANDS 421 32
SE

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024